Highlights

Mar. 12 Abivax Denies Reported Takeover Talks With AstraZeneca MT
Mar. 12 Abivax Denies La Lettre Report of AstraZeneca Exclusivity MT
Mar. 12 Abivax Denies La Lettre Report of AstraZeneca Exclusivity, Bloomberg Reports MT
Mar. 12 Abivax denies AstraZeneca takeover rumors reported by French media RE
Mar. 12 AstraZeneca in pole position to acquire Abivax Zonebourse
Feb. 21 Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease At Ecco 2026 CI
Jan. 20 Abivax CEO Says No Talks on Acquisition Deal Amid Reported Lilly Interest MT
Jan. 20 Abivax CEO Plays Down Eli Lilly Takeover Talk MT
Jan. 20 Abivax CEO dismisses 'noise' around rumored Eli Lilly bid RE
Jan. 20 Euro-American Tensions Continue to Weigh on Stock Markets Zonebourse
Jan. 20 Wise and Virbac Benefit from Quarterly Results, Valneva and Logitech Slide Zonebourse
Jan. 20 Abivax May Have a New... European Suitor Zonebourse
Jan. 14 Historic Morning Record for the CAC 40 Zonebourse
Jan. 13 French Government Says Eli Lilly Made No Contact Regarding Abivax Takeover MT
Jan. 12 France Says Yet to Receive Investment Screening Dossier from Lilly Over Potential Abivax Bid MT
Jan. 12 France denies contact with Eli Lilly over reported $17.5 billion Abivax deal RE
Jan. 12 French Government Says Eli Lilly Made No Contact Regarding Abivax Takeover MT
Jan. 12 Abivax Surges on Takeover Rumors, French Finance Ministry Not Informed RE
Jan. 12 France has had no request for investment approval in biotech Abivax - official RE
Jan. 12 France: Bercy Not Informed of Any Request Regarding Abivax, Sought After by Eli Lilly RE
Jan. 12 Fed Chair Powell Faces US DOJ Criminal Probe, Equity Futures Waver Pre-Bell MT
Jan. 12 Independence, Under Review Zonebourse
Jan. 12 Top Premarket Gainers MT
Jan. 12 Correction to Eli Lilly Headline DJ
Jan. 12 Abivax Shares Rise Pre-Bell as Eli Lilly Said to Prepare $17.5 Billion Takeover Bid MT
No results for this search
SPRING SALE - 40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW